Dernières nouvelles pour Grace Therapeutics (NASDAQ:GRCE) Stock

Grace Therapeutics

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Grace Therapeutics Inc

WIIM

DATS

DatChat shares are trading lower after the company announced an agreement to sell $6 million worth of common stock through an "at the market offering" program.

Lake Street analyst Jaeson Schmidt maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Buy and raises the price target from $7 to $11.

News

Price Target

Analyst Ratings

AIOT

Lake Street Maintains Buy on PowerFleet, Raises Price Target to $11

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) inked a Letter of Intent with France's Commissariat à l&#8217;énergie atomique et aux énergies alternatives (CEA) to collaborate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43615743/amd-and-the-commissariat-l-nergie-atomique-et-aux-nergies-alternatives-cea-to-collaborate-on-the-f" rel="noreferrer noopener">on advanced AI computing technologies</a>.
The partnership aims to develop energy-efficient systems for high-performance AI workloads across sectors such as energy and medicine.
As part of this initiative, AMD and CEA will collaborate to advance next-generation AI computing infrastructure.
Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43505678/amds-ai-ambitions-face-nvidias-dominance-analysts-see-growth-but-challenges-remain" rel="noreferrer noopener">AMD&#8217;s AI Ambitions Face NVIDIA&#8217;s Dominance—Analysts See Growth, But Challenges Remain</a>
Ralph Wittig, Corporate Fellow and head of research, AMD said, &#8220;Through this collaboration with CEA and leading French engineers, we aim to bring cutting-edge AI research closer to real-world applications by advancing system architectures that meet the demands of tomorrow&#8217;s AI workloads, while growing the joint research and development opportunities between the U.S. and France.&#8221;
Julie Galland, Director of the Technological Research division at CEA, stated, &#8221;Our collaboration with AMD represents a significant step toward fostering international cooperation in high-performance computing, bringing together world-class expertise to address the growing demands of AI workloads.&#8221;
&#8220;By combining CEA&#8217;s research leadership with AMD&#8217;s cutting-edge technology, we aim to develop breakthrough solutions that will shape the future of AI computing in Europe and beyond.&#8221;
Last week, AMD reported fourth-quarter revenue of $7.66 billion, beating&nbsp;analyst estimates of $7.53 billion, and adjusted earnings of $1.09 per share, beating <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43480688/amd-q4-earnings-revenue-beat-eps-beat-data-center-continued-growth" rel="noreferrer noopener">analyst estimates of $1.08 per share</a>.
Investors can gain exposure to the stock via Amplify Video Game Leaders ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAMR#NYSE">GAMR</a>) and VanEck Video Gaming and eSports ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPO#NASDAQ">ESPO</a>).
Price Action: AMD shares are down 1.18% at $111.78 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43608591/taiwan-semiconductors-trillion-dollar-valuation-the-chipmaker-enabling-ai-boom" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor&#8217;s Trillion-Dollar Valuation: The Chipmaker Enabling AI Boom</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Contracts

ESPO

GAMR

AMD Expands AI Research With CEA Partnership, Aiming for Energy-Efficient Computing

<a href="https://www.youtube.com/watch?v=aavRKJYuJkE" title="https://www.youtube.com/watch?v=aavRKJYuJkE">https://www.youtube.com/watch?v=aavRKJYuJkE</a>

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says Fed Can't Control Long Rates

SQNS

Sequans Communications shares are trading lower after the company reported worse-than-expected Q4 adjusted EPADS results.

Fed Chair Powell Says Not For Me To Say If We've Experienced A Soft Landing; Have Not Experienced A Hard Landing

Silence Therapeutics shares are trading lower after Goldman Sachs initiated coverage on the stock with a Sell rating and announced a price target of $6.

Loop Capital analyst Chris Dankert maintains Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) with a Buy and lowers the price target from $155 to $145.

Loop Capital Maintains Buy on Belden, Lowers Price Target to $145

MYNZ

Mainz Biomed shares are trading higher after the company announced through a partnership the launch of enhanced coloalert colorectal cancer screening.

<a href="https://www.benzinga.com/personal-finance/25/01/43276105/trumps-tax-plan-could-slash-social-security-benefits-33-by-2035-ramsey-show-host-george-kamel-weighs-in">President Donald Trump</a> has placed a hold on tens of billions of dollars in federal funding, affecting projects in clean energy, conservation, and transportation across the United States. While the administration argues these pauses are necessary for budget reassessment, critics say they are creating uncertainty for thousands of workers and local economies.
<h2 class="wp-block-heading">Billions in Federal Spending on Hold</h2>
A Reuters analysis found that Trump&#8217;s funding freeze has affected a broad range of initiatives, from energy efficiency projects to major infrastructure improvements. One example is the &#8220;Long Bridge&#8221; project in Virginia, a $2.3 billion railway expansion that would increase passenger and freight services. The funding pause has left it in limbo, raising concerns among lawmakers and project managers.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
The funding freeze is part of a broader effort by the administration to assess and potentially cut spending from two major legislative packages passed during the <a href="https://www.benzinga.com/general/social-media/25/01/43047973/tiktok-ban-decision-left-to-trump-by-biden-administration-what-this-means-for-170-million-us-users-and-big-tech">Biden administration</a>, including the Inflation Reduction Act. House Speaker Mike Johnson defended the move, saying that the executive branch has the right to review spending and ensure taxpayer dollars are used effectively.
<h2 class="wp-block-heading">Economic and Employment Impacts</h2>
Many officials and project managers say the delays are putting thousands of jobs at risk. Mike Foley, an energy project lead in Cuyahoga County, Ohio, told Reuters his team has more than $100 million in paused funding. "I need to hire engineers, and I can't do that," he said.
Farmers, too, are feeling the effects. The Iowa Soybean Association, which had secured funding to help farmers implement conservation practices, says millions of dollars are now at risk. "This suspension puts the program and its participating farmers in jeopardy," President Brent Swart reportedly wrote in a letter to Congress.&nbsp;
Trending: Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares"> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</a>
<h2 class="wp-block-heading">Legal and Political Disputes</h2>
<a href="https://www.benzinga.com/markets/cannabis/25/01/42913566/john-fetterman-first-democratic-lawmaker-to-accept-trump-invitation-to-mar-a-lago">Democratic lawmakers</a> argue that these funding holds amount to &#8220;impoundment,&#8221; which they claim is illegal without congressional approval. A decades-old law requires the president to notify Congress before withholding congressionally approved funds. A federal court temporarily blocked Trump's broad freeze, but the administration has continued to maintain that its spending review process is within legal bounds.
Sen. Patty Murray of Washington, a senior Democrat on the Senate Appropriations Committee, said her party is prepared to push back against the funding holds. "We will speak out, we will press this administration, we will open investigations, and we will demand accountability," she told reporters recently.
<h2 class="wp-block-heading">Impact on State and Local Governments</h2>
Several states and municipalities are left in uncertainty as they try to move forward with planned projects, Reuters reported. In Ohio, a small town hoped to replace an aging coal power plant with solar panels and battery storage, a project that was expected to create 200 jobs. That initiative is now on hold. Similarly, in Prichard, Alabama, officials are relying on federal grants to fix an aging water system, but with no guarantee of funding, they face ongoing infrastructure challenges.
See Also: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
<h2 class="wp-block-heading">What's Next?</h2>
While the Trump administration has rescinded some parts of the <a href="https://www.benzinga.com/government/regulations/25/01/43292056/judge-blocks-trumps-order-to-freeze-federal-grant-money">funding freeze</a> following court intervention, uncertainty remains. The president has made clear that he intends to pursue significant federal spending cuts, raising concerns about the long-term future of these projects. Businesses, local governments, and environmental groups continue to watch closely, hoping for clarity on when—if ever—these funds will be released.
As the political battle continues, affected communities are left waiting, wondering if the funding they were promised will ever materialize.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>

Trump Freezes Billions In Federal Funding—Jobs and Projects In Clean Energy, Conservation, And Transportation Left In Limbo

Fluor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) short percent of float has fallen 6.87% since its last report. The company recently reported that it has 8.64 million shares sold short, which is 6.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fluor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739288731_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fluor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fluor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fluor's peer group average for short interest as a percentage of float is 5.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Fluor's Recent Short Interest

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an average annual return of 34.45%. Currently, Viking Therapeutics has a market capitalization of $3.28 billion. 
Buying $100 In VKTX: If an investor had bought $100 of VKTX stock 5 years ago, it would be worth $441.38 today based on a price of $29.45 for VKTX at the time of writing.
<h3>Viking Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739288728_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VKTX

$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 31.52% since its last report. The company recently reported that it has 1.05 million shares sold short, which is 3.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739288726_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 3.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Teleflex?

Fed Chair Powell Says We Are In A Pretty Good Place With This Economy; Want To Make More Progress On Inflation; Don't See Any Reason To Be In A Hurry; High Mortgage Rates Are Less Related To Fed Policy But To Treasury Yields; Once We Lower Rates, Mortgage Rates Will Come Down; Don't Know When That Will Be; We Are Not In Recession

Vertiv Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) short percent of float has risen 3.54% since its last report. The company recently reported that it has 13.61 million shares sold short, which is 4.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertiv Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739288721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertiv Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertiv Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertiv Hldgs's peer group average for short interest as a percentage of float is 10.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(VRT) - Analyzing Vertiv Hldgs's Short Interest

Federal Reserve Chair Jerome Powell reiterated on Tuesday that policymakers are in no "hurry" to adjust interest rates, citing lingering inflation pressures despite significant progress toward the Fed's 2% inflation goal.
Speaking before the Senate Banking Committee in Washington, Powell described the current economic landscape as one where "the economy is strong overall." with a labor market that has cooled from its overheated state but remains resilient.
Over the past four months, payroll job gains averaged 189,000 per month, while the unemployment rate held steady at 4% in January. Powell indicated that "the labor market is not a source of significant inflationary pressures."
On inflation, Powell highlighted a notable decline over the past two years but stressed that "inflation remains somewhat elevated."
The latest Personal Consumption Expenditures price index showed a 2.6% year-over-year increase as of December, with core PCE rising 2.8%, excluding volatile food and energy costs. 
<h3 class="wp-block-heading">Powell Stresses Cautiousness In Interest Rate Policy</h3>
Since September, the Federal Open Market Committee has lowered the policy rate by a full percentage point from its peak. 
Powell described this shift as "appropriate in light of the progress on inflation and the cooling in the labor market."
Despite these moves, Powell reiterated that "we do not need to be in a hurry to adjust our policy stance." 
He stated that reducing interest rates &#8220;too fast or too much&#8221; could derail progress on inflation, while moving too slowly or too little "could unduly weaken economic activity and employment."
Going forward, the Fed will continue to remain data dependent, before making further policy adjustments. 
[This article will be updated as new information emerges]

Econ #s

Fed's Powell Reiterates No 'Hurry' To Cut Interest Rates As Inflation Remains 'Somewhat Elevated'

ORMP

Oramed Pharmaceuticals shares are trading higher after the company announced a definitive agreement to spin off its protein oral delivery technology into a joint venture with Hefei Tianhui Biotech.

JMP Securities analyst Roy Buchanan reiterates Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Market Outperform and maintains $21 price target.

Reiteration

ENTA

JMP Securities Reiterates Market Outperform on Enanta Pharma, Maintains $21 Price Target

Fed Chair Powell Says CFPB Has Responsibility For Consumer Compliance For Large Banks; Fed Does Not Enforce Consumer Protection For Things Like Money Transfers At Big Banks; That's Cfpb; On Technology Firms, Fed Does Not Have Jurisdiction; Fed Has No Role In Consumer Protection Unless You Are A Fed-member Bank With $10b Or Less In Assets; There Is A Gap In Consumer Compliance Protection If CFPB Were Shut

Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) will release its fourth-quarter financial results after the closing <a href="https://www.benzinga.com/quote/LYFT/earnings">bell on Tuesday, Feb. 11</a>.
Analysts expect the San Francisco, California-based company to report a quarterly loss at 1 cent per share, versus a year-ago loss of 6 cents per share. Lyft projects quarterly revenue of $1.54 billion, compared to $1.22 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Lyft shares gained on Monday following a report indicating the company could launch robotaxis as soon as 2026.
Lyft shares gained 6.7% to close at $15.12 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>UBS analyst Lloyd Walmsley maintained a Neutral rating and cut the price target from $18 to $16 on Feb. 3, 2025. This analyst has an accuracy rate of 86%.</li>
<li>B of A Securities analyst Michael McGovern maintained a Buy rating and cut the price target from $21 to $19 on Jan. 29, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Wells Fargo analyst Ken Gawrelski maintained an Equal-Weight rating and lowered the price target from $17 to $14 on Jan. 16, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Wedbush analyst Scott Devitt maintained a Neutral rating and cut the price target from $20 to $18 on Jan. 6, 2025. This analyst has an accuracy rate of 84%.</li>
<li>Benchmark analyst Michael Ward upgraded the stock from Hold to Buy with a price target of $20 on Jan. 6, 2025. This analyst has an accuracy rate of 76%.</li>
</ul>
Considering buying LYFT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="568" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11034339/image-86-1024x568.png" alt="" class="wp-image-776049" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11034339/image-86-1024x568.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11034339/image-86-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11034339/image-86-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11034339/image-86.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Earnings

Markets

LYFT

Lyft Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Grace Therapeutics GAAP EPS of -$0.30 beats by $0.06

Acasti Pharma, Inc. ( ($GRCE) ) has released its Q2 earnings. Here is a breakdown of the information Acasti Pharma, Inc. presented to its investors...

Grace Therapeutics Reports Steady Progress and Financials

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Grace Therapeutics (GRCE – Research Report). The compa...

Craig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)

Grace Therapeutics (GRCE) will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists to be held De...

Grace Therapeutics to exhibit at ASHP Conference

Grace therapeutics announces private placement financing of $30 million

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit when...

Grace Therapeutics announces results from Phase 3 STRIVE-ON trial

Grace Therapeutics meets main goal in late stage trial for its aneurysmal SAH treatment

GRCE

Health Care

Press Releases

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

Grace Therapeutics Announces Second Fiscal Quarter 2025  Financial Results, Provides Business Update

Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Financing

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

ACST

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Impact BioMedical

IGC Pharma

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SCYNEXIS

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Comments

Grace Therapeutics

Actualités

Dernières nouvelles pour Grace Therapeutics (NASDAQ:GRCE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL